阿托伐他汀钙联合降脂通脉胶囊治疗高脂血症临床观察

目的 观察阿托伐他汀钙联合降脂通脉胶囊治疗高脂血症的疗效与安全性.方法 将80例高脂血症患者随机分为两组.治疗组40例,降脂通脉胶囊,3粒/次,3次/d口服,并于每晚睡前口服阿托伐他汀钙20mg.对照组40例,每晚睡前口服阿托伐他汀钙20 mg.两组均以4周为一个疗程,共持续8周.观察服药前及服药后第4、8周末血脂指标（TC、TG、LDL-C、HDL-C）、肝肾功能、肌酸激酶及不良反应.结果 两组患者治疗前血脂水平无明显差异（P＞0.05）.用药后两组患者TC、TG和LDL-C水平较用药前均明显降低,且8周后降低更显著（P均＜0.05）;与对照组比较,治疗组用药4周及8周末TC、TG和LDL-C均显著降低（P均＜0.05）;治疗后两组HDL-C水平均不同程度升高,且8周后更显著（P均＜0.05）,但两组间无明显差异（P＞0.05）;治疗组总有效率为90.00％（36/40）,显著高于对照组的67.50％（27/40）,差异有统计学意义（P＜0.05）;治疗期间两组均未观察到明显不良反应.结论 阿托伐他汀钙联合降脂通脉胶囊有明显降低TC、TG、LDL-C和升高HDL-C的作用,且不良反应轻微,使用安全.

Clinical observation of atorvastatin calcium combined with Jiangzhitongmai capsules in treatment of hyperlipidemia

Objective To observe the efficacy and safety of atorvastatin calcium combined with Jiangzhitongmai cap- sules in the treatment of hyperlipidemia. Methods Eighty patients with hyperlipidemia were randomly divided into two groups. The treatment group, consisting of 40 patients, took Jiangzhitongmai capsules orally 3 pieces/day and 3 times/ day and took atorvastatin calcium 20 mg orally every night before sleep. The control group, consisting of 40 patients, took atorvastatin calcium 20 mg orally every night before sleep. For both groups, 4 weeks was 1 treatment course and the treatment lasted for 8 weeks. The blood lipid parameters （TC, TG, LDL-C and HDL-C）, liver and kidney function, creatine kinase and adverse reactions before medication and at the end of the 4th and 8th week of medication were ob- served. Results The two groups of patients were not significantly different in the pre-treatment blood lipid level （P〉 0.05）. After medication, the TC, TG and LDL-C levels of both groups reduced significantly compared to those before medication and reduced more significantly after 8 weeks （P〈0.05 for all）. The TC, TG and LDL-C levels of the treat- ment at the end of the 4th and 8th week of medication reduced significantly compared to those of the control group （P〈 0.05 for all）. After treatment, the HDL-C levels of both groups increased to varying degrees and increased more signifi- cantly after 8 weeks （P〈0.05 for all）, but there were no significant differences between the two groups （P〉0.05）. The to- tal effective rate of the treatment group was 90.00% （36/40）, which was significantly higher than the 67.50% （27/40） of the control group, with statistically significant difference between the two groups （P〈0.05）. During treatment, no obvious adverse reactions were observed in either group. Conclusion Atorvastatin calcium combined with Jiangzhi ongmai capsules have obvious effect on reducing TC, TG and LDL-C and increasing HDL-C, causes mild adverse reactions and is safe to